Risk factor
Negligible price volatility
Profitability factor
Overvalued vs peers
About
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, reasonab
Target Price
The average target price of ABBV is 245 and suggests 8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Buy
Sell